title: Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection.
abstract: Zidovudine pharmacokinetics were determined in 16 children with human immunodeficiency virus infection who were being treated intravenously and orally on an intermittent schedule (every 6 hours). The intravenous doses studied were 80 (n = 3), 120 (n = 4), and 160 (n = 5) mg/m2/dose, infused over 1 hour. Fourteen patients were monitored after an oral dose of zidovudine at 120 (n = 2), 180 (n = 7), or 240 (n = 5) mg/m2/dose. Zidovudine was assayed with a reverse-phase high-pressure liquid chromatography method. Zidovudine disappearance after intravenous administration was rapid and biexponential, with half-lives of 14 and 90 minutes and a total clearance of 641 +/- 161 ml/min/m2. The volume of distribution at steady state was 45 +/- 28 L/m2. These pharmacokinetics parameters are very similar to those reported in adults. When administered orally, zidovudine was rapidly absorbed. The fraction of the oral dose that was bioavailable was 0.68 +/- 0.25, so that a 50% increment in the dose, in the conversion from intravenous to oral administration, resulted in plasma zidovudine concentrations after oral dosing that were nearly identical to those achieved with the 1-hour intravenous infusion. However, a dose of 180 mg/m2 given orally every 6 hours maintained plasma zidovudine concentrations in the target range of 1 mumol/L for less than half of the dosing interval. Other schedules, routes of administration, or oral drug formulations may have to be considered if sustained continuous exposure to micromolar zidovudine concentrations is desired.
authors.affiliation: Pediatric Branch, National Cancer Institute, Bethesda, Maryland 20892.
authors.forename: F M
authors.initials: FM
authors.lastname: Balis
authors.forename: P A
authors.initials: PA
authors.lastname: Pizzo
authors.forename: J
authors.initials: J
authors.lastname: Eddy
authors.forename: C
authors.initials: C
authors.lastname: Wilfert
authors.forename: R
authors.initials: R
authors.lastname: McKinney
authors.forename: G
authors.initials: G
authors.lastname: Scott
authors.forename: R F
authors.initials: RF
authors.lastname: Murphy
authors.forename: P F
authors.initials: PF
authors.lastname: Jarosinski
authors.forename: J
authors.initials: J
authors.lastname: Falloon
authors.forename: D G
authors.initials: DG
authors.lastname: Poplack
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000378:metabolism*; D000284:Administration, Oral; D001682:Biological Availability; D002648:Child; D002675:Child, Preschool; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006207:Half-Life; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D007408:Intestinal Absorption; D008297:Male; D008657:Metabolic Clearance Rate; D015215:Zidovudine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D015215:Zidovudine